Summary The anti-breast carcinoma monoclonal antibody (MAb), NCRC-11 defines a polymorphic epithelial mucin (PEM) which is elevated in the circulation of advanced breast carcinoma patients. Here we describe the purification and partial characterisation of this component from patients' sera and its use in the production of a second generation MAb, C568 (IgM). Pooled sera was fractionated by immunoaffinity and size-exclusion chromatography and the purity of preparations assessed by sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) and immunoblotting. Serum-derived PEM shows a similar pattern of electrophoretic mobility to PEM isolated from primary breast tumour tissue and migrates as several bands in 4% SDS polyacrylamide gels (Mr > 400,000). The epitope expression of PEMs isolated from either source is also similar, with both bearing topographically distinct determinants for several anti-mucin MAbs. The immunoreactivities of antibodies C568 and NCRC-11 were unaffected by boiling, reduction and alkylation, or by enzyme desialylation of PEM. Periodate oxidation and proteolytic digestion have suggested that the antigenic determinant for C568 is carbohydrate in nature whilst that of NCRC-II is peptidic. In accord with the mucinous nature of the molecule, serum-derived PEM is susceptible to reductive P-elimination, elutes in the void volume of a Sepharose CL-4B column and has a buoyant density of 1.45 g ml-'.
In Western countries breast carcinoma affects an estimated one in fourteen women and is responsible for the highest female mortality rate due to any form of malignancy (Tagnon, 1986 ). Consequently, the immunological detection of a carcinoma-associated marker which differentiates normal from malignant cells has become increasingly important. Since the advent of monoclonal antibody (MAb) technology, a considerable number of antibodies have been described which recognise breast carcinoma-associated antigens. These antigens show marked variations in molecular weight and tissue distribution and consequently, the antibodies defining them vary widely in their selectivity towards malignant tissue. Several of these antibodies define epitopes on a high molecular weight mucin which is peculiar to the luminal surface of glandular epithelial cells or their secretions and hence is also associated with certain carcinomas. Originally purified from human milk, this component has been termed PAS-O by Shimizu and Yamauchi (1982) , EMA (epithelial membrane antigen) by Heyderman et al., (1979) , by Hilkens et al. (1984) and MSA (mammary serum antigen) by Stacker et al. (1988) . Karlsson et al. (1983) first reported that the mucin exhibits a genetic polymorphism which was later shown to exist at both the protein and DNA level (Swallow et al., 1987; Gendler et al., 1987, respectively) . Consequently, Gendler et al., (1988) have named the mucin polymorphic epithelial mucin, or PEM, a term which aptly describes its properties.
NCRC-l1 is a murine MAb (IgM) originally produced against metastatic breast carcinoma cells (Ellis et al., 1984) . This antibody reacts with a variety of normal and malignant tissues of epithelial origin and immunocytochemical studies have shown that in malignant tissue there exists a direct relationship between the intensity of staining and patient survival (Ellis et al., 1985) . The antigen defined by NCRC-l bears multiple epitopes for several anti-mucin MAbs and also displays the same molecular weight, tissue distribution and genetic polymorphism as PEM. Furthermore, NCRC-l1 has recently been shown to react with the core protein of PEM confirming the notion that the NCRC-l1 defined antigen is indeed PEM (Price et al., 1990) .
Of clinical interest, it has been reported that PEMs are elevated in the circulation of advanced breast carcinoma patients (Burchell et al., 1984; Hayes et al., 1985; Hilkens et al., 1986; Price et al., 1987) and these findings have promoted investigation into its potential as a prognostic or diagnostic indicator. The present study describes the purification and partial characterisation of PEM isolated from advanced breast carcinoma patients' sera and its use in the production of a second-generation MAb, C568.
Materials and methods
Monoclonal antibodies NCRC-I 1 monoclonal antibody (IgM) was raised against dissociated breast carcinoma cells as described in detail by Ellis et al. (1984) .
MAb C568 (IgM) was derived from a fusion of mouse myeloma cells with spleen cells of a BALB/c mouse immunised against PEM isolated from sera. Hybridoma supernatants were screened by radioimmunoassay (RIA) for reactivity against purified serum PEM and positive clones selected for on this basis. Both antibodies were purified from ascitic fluids by Sepharose-Lentil lectin affinity chromatography (Pharmacia, Uppsala, Sweden).
Other MAbs used in this study and which also identify mucinous antigens are listed in Table I (Figure 1 , for example).
Isolation of circulating PEM
An immunoadsorbent column was prepared by coupling 20 mg NCRC-11 antibody to 20 ml CNBr-activated Sepharose (Pharmacia). For each purification, 50-100 ml of pooled advanced breast cancer patients' sera was filtered, clarified (180,000 g, 1 h) and delipidated. The sera were diluted 10-fold in 0.1 M Tris-HCI (pH 7.6) then passaged through the affinity column which had been equilibrated in the same buffer. The column was then washed with buffer and non-specifically bound material removed with a wash containing 1 M NaCl. Bound material was eluted using 0.1 M diethylamine (pH 11.5) and eluted fractions (2 ml) neutralised with 1 M Tris-HCI (pH 7.6). Ten J1l aliquots of each fraction were then assayed for PEM activity by Solid Phase RIA. The density of each fraction was determined gravimetrically using an analytical balance.
Chemical and enzymatic treatments
Reductive P-elimination of lyophilised PEM was performed using 0.1 M NaOH with or without 1 M NaBH4. After incubation (25 h, 37C) the solutions were neutralised with glacial acetic acid and dialysed against PBS. Mild periodate oxidation was accomplished by incubating PEM-coated plates with 0, 1, 10 and 100 mM NaIO4 in acetate buffer (50 mM, pH 4.5) for 12 h at 4°C in the dark. Following a brief rinse with acetate buffer, the plates were incubated with 50 mM sodium borohydride in PBS for 30 min at room temperature.
(This treatment reduces aldehyde groups to alcohols and prevents non-specific cross-linking of antibody to antigen.) Plates were then washed and assayed for PEM activity by RIA.
The following enzymatic conditions were used: Clostridium perfringens neuraminidase (type X) 100, 10, 0 units ml ' in acetate buffer (0.2 M, pH 5.5) containing 1 mM phenylmethlysulphonyl fluoride (PMSF), 2 h, 37°C; trypsin, chymotrypsin, pronase E (protease, type XIV, pre-heated 60C, 1 h), subtilisin (protease, type XXIV) and papain (containing 5 mM L-cysteine), all at 100, 10, 1, 0.1 and 0 units ml' in 0.1 M Tris-HCI (pH 8.0) containing 1 mM CaCl2 and incubated for 1 h and 18 h at 37°C. All enzymes were obtained from the Sigma Chemical Co.
Results

Purification of circulating PEM
Pooled advanced breast cancer patients' sera was applied to an NCRC-I 1 affinity column. Fractions eluted from the column and assayed for PEM activity (Figure 2 ) established that recoverable levels of circulating PEM were exhausted after 4-6 sequential passages through the column. SDS-PAGE and Western blot analyses of affinity purified material revealed two contaminating proteins in the preparation (Figure 1 , track 2) which were tentatively identified as IgG and IgM. These were confirmed to be human antibodies by running the corresponding normal standards (non-reduced human IgG and IgM) and by immunostaining blots using specific immunoconjugates for human Ig's ( Figure 1 , tracks 2-4). We have since established that these antibodies are normal heterophile antibodies cross-reactive with the murine NCRC-1 1 antibody bound to the column (O'Sullivan et al., in preparation).
In order to remove these contaminants, size exclusion chromatography using Sepharose CL-4B was performed on the affinity purified material. PEM elutes coincident with the void volume indicating an apparent molecular weight in excess of 2,000 kDa. This unexpectedly high molecular weight elution profile is most likely the result of aggregation of individual molecules and has also been described by other workers (Ho et al., 1988; Miotti et al., 1985; Kalthoff et al., 1986) . Although the majority of contaminating antibody was eliminated by this means, a proportion of aggregated IgM co-eluted with the mucin. However, subsequent experiments have shown that, by reducing the contaminating IgM into its monomeric sub-units, it could be displaced into the included volume of an S300 gel filtration column thus separating it from the peak of PEM activity which remains in the void volume in S300 gel (as with CL-4B). This was achieved by reduction and alkylation of affinity purified mucin preparations prior to size exclusion chromatography. Individual fractions eluting from the S300 column were assayed separately, by (Figure 2 ).
Epitope expression of PEMs A number of MAbs (see Table I ) raised against various immunogens and known to be reactive with PEMs isolated from breast carcinoma cells were tested, by RIA, for their reactivity against PEMs isolated from both breast carcinoma cells and patients' sera. Figure 4 demonstates that the overall profile of antibody reactivity is similar for antigen isolated from either source. Clearly, the antigenic determinant for Figure 5, track 2) . Following neuraminidase treatment of serum PEM, a marked decrease in electrophoretic mobility was observed, with the molecule barely entering the gel ( Figure 5, track 1) . No apparent change in antigenicity was observed although there was a loss in resolution of the phenotypic bands. To investigate the role of sialic acid residues in relation to individual epitope structures, epitope expression studies on desialylated PEM were undertaken. 1 2 Figure 5 Western blot anlysis of neuraminidase treated PEM. Purified serum PEM was subjected to neuraminidase digestion as described in Materials and methods. Digested and undigested samples were electrophoresed on a 4% polyacrylamide gel and then transferred on to nitrocellulose. After blocking, the nitrocellulose was incubated with NCRC-1 1 antibody followed by peroxidase conjugated anti-mouse Ig and developed with the peroxidase substrate 3-amino-9-ethyl carbazole/H202. Track 1 neuraminidase treated PEM; track 2, untreated PEM. Monoclonal antibodies in atissue culture supernatants and bascitic fluids were tested for their capacity to inhibit the binding of radiolabelled NCRC-I I antibody at the dilutions shown. CDilutions of competing antibodies were predetermined to ensure saturation of the antigen at least at the highest concentration used. (Bobbit, 1956 ). In such a manner it is possible to destroy carbohydrate epitopes leaving intact only those epitopes common to the protein moiety and hence establish the nature of PEM epitopes. Figure 6 represents the effect oxidative cleavage of PEM has on the binding of several MAbs relative to their activity towards untreated material. The binding of MAb C568 to treated antigen was virtually abolished except at the lowest concentration of periodate used (1 mM). Likewise, 115D8 reactivity was markedly reduced. Conversely, SM3, which is unreactive with native serum-derived PEM, gained binding activity upon periodate treatment of the mucin. MAbs M8 and HMFG-2 also showed some increase in binding at the lower concentrations of periodate. The epitopes identified by these antibodies involve the protein moiety be noted, however, that periodate oxidation cleaves only those saccharides with vicinal hydroxyls, therefore results from periodate treatment alone should be interpreted with caution since it is possible that certain epitopes may reside upon periodate-resistant sugars (e.g 1+3 linked Gal).
Buoyant density of PEM Well-documented evidence reports that mucins exhibit higher densities than other proteins and glycoproteins, usually in the range of 1.4-1.5 g ml-' (Starkey et al., 1974) . Figure 7 shows fractions recovered after CsCl density gradient centrifugation of serum PEM which were assayed for PEM activity after determination of their density. PEM was recovered in a band corresponding to a density of 1.40-1.45 g ml-' with the peak occuring around 1.43 g ml-'. This is in accord with the expected value for a mucinous protein.
Reductive 13-elimination and protease digestion ofpurified serum antigen
Alkaline hydrolysis of PEM under reducing (0.1 N NaOH + 1 M NaBH4) or non-reducing conditions (0.1 N NaOH) substantially decreased the immunoreactivity of NCRC-l 1 antibody but had little effect on that of C568 (Table IV) . Proteolytic digestions using the proteases and conditions described in Table IV (Ellis et al., 1984) . That the mucin was detectable in low levels in the pooled sera of normal individuals (Figure 2) In SDS polyacrylamide gels, PEM migrates as a series of bands differing slightly in electrophoretic mobility. This is due to the polymorphism which is seen at both the DNA and protein level (Swallow et al., 1987; Gendler et al., 1987) . Each band represents one of several phenotypes which are the products of a number of codominant alleles present at a single gene locus. In addition to this polymorphism, variations in glycosylation, in particular differential sialylation, gives rise to a highly heterogeneous molecular species with respect to both size and charge.
Desialylation of PEM with neuraminidase resulted in a marked decrease in electrophoretic mobility ( Figure 5 ). This occurs due to removal of the intrinsic negative charge which, in the intact molecule, enhances its migration in an electrophoretic field. Thus, the 'apparent' Mr of around 400 kDa of intact PEM is most likely an under-estimation of its true molecular weight.
A major characteristic of mucinous glycoproteins is that they contain a majority of 0-linked glycans (Gottschalk, 1972) and, in the case of PEMs, only a small proportion of N-linked sugars (Hilkens & Buijs, 1988) . Evidence for the presence of 0-linked glycans is based on the observed Pelimination mechanism which occurs under mild conditions of alkali and cleaves carbohydrate residues from the 0-substituted seryl and threonyl residues on the polypeptide chain. Under these conditions the protein core is denatured and this explains the marked decrease in NCRC-11 immunoreactivity following P-elimination of serum PEM (Table IV) .
The determination of a high buoyant density (1.43 g ml-') is also consistent with a mucinous nature (Figure 7) . The (Foster & Neville, 1984) . Antibody SM3, which was raised against deglycosylated milk mucin and shows selectivity towards malignant tissue , 1989) . Differential glycosylation of epithelial mucins in tumours may lead to the exposure of protein epitopes allowing selective binding of MAbs such as SM3. This would infer that the glycoslyation pattern of circulating PEM is not necessarily that of the malignant phenotype although this requires further evaluation. Oxidative cleavage of glycans by periodate treatment suggested that the antigenic determinants for C568 is carbohydrate in nature whilst that of NCRC-1 1 is peptidic and these findings were further substantiated by protease digestions (Table IV) . By way of confirmation of these proposals, we have recently shown that the NCRC-1 1 antibody reacts with synthetic peptide heptamers with sequences based upon that reported for the core protein of PEM . C568, as expected, does not react with these sequences (Price et al., 1990) . Gendler et al. (1988) proposed that PEMs each share the same core protein which is coded for by a single polymorphic gene and exists in a linear conformation consisting of tandem repeats of 20 amino acids. The number of repeated sequences, which varies between individuals, is determined by the observed genetic polymorphism and thus governs the size of the molecule. An extended rod-like conformation would be consistent with the resistance of serum PEM epitopes to boiling (Table IV) since the molecule is already in an unfolded form stabilised by extensive glycosylation.
Along the length of the core protein are attached numerous differentially glycosylated side chains which may develop tumour-associated variations. Altered patterns of glycosylation due to incomplete synthesis or neosynthesis of glycans; aberrant processing of specific glycosyl transferases and/or tumour glycosidase activity might all result in the development of new tumour-associated epitopes. The elucidation and characterisation of such tumour markers is fundamental to research into the structure and expression of glycoproteins during neoplastic progression. Human PEM from sera carries potentially clinically relevant epitopes and offers a model system for investigating the biosynthesis and release of a carcinoma-associated mucin.
